Overview

* BioCardia ( BCDA ) Q3 net loss decreases to $1.5 mln from $1.7 mln last year

* Company closed $6 mln financing to support CardiAMP cell therapy initiatives

* Research and development expenses rise due to CardiAMP HF trial activities

Result Drivers

* FINANCING SUPPORT - $6 mln financing supports CardiAMP cell therapy approvability discussions and trials, per CEO Peter Altman

* R&D EXPENSES - Increased R&D expenses driven by CardiAMP HF trial activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$1.48

Income mln

Q3 Basic -$0.24

EPS

Q3 -$1.49

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for BioCardia Inc ( BCDA ) is $15.50, about 91.4% above its November 11 closing price of $1.33

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)